Compass Therapeutics Inc. (CMPX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) has a cash flow conversion efficiency ratio of -0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.85 Million) by net assets ($209.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check CMPX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Compass Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Compass Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. See Compass Therapeutics Inc. (CMPX) shareholders funds for net asset value and shareholders' equity analysis.
Compass Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compass Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smcp SAS
PA:SMCP
|
0.110x |
|
Eik fasteignafélag hf
IC:EIK
|
0.017x |
|
Vox Royalty Corp.
TO:VOXR
|
0.024x |
|
Okea ASA
OL:OKEA
|
0.729x |
|
Shih Her Technologies
TWO:3551
|
-0.157x |
|
Shihlin Paper Corp
TW:1903
|
0.004x |
|
Stack Capital Group Inc
TO:STCK
|
-0.013x |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
N/A |
Annual Cash Flow Conversion Efficiency for Compass Therapeutics Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Compass Therapeutics Inc. from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Compass Therapeutics Inc. (CMPX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $125.23 Million | $-44.85 Million | -0.358x | -30.98% |
| 2023-12-31 | $148.54 Million | $-40.62 Million | -0.273x | -45.55% |
| 2022-12-31 | $181.64 Million | $-34.12 Million | -0.188x | -33.82% |
| 2021-12-31 | $140.08 Million | $-19.67 Million | -0.140x | +79.08% |
| 2020-12-31 | $39.95 Million | $-26.80 Million | -0.671x | -350.72% |
| 2019-12-31 | $-118.60 Million | $-31.74 Million | 0.268x | -32.64% |
| 2018-12-31 | $-84.77 Million | $-33.68 Million | 0.397x | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways… Read more